Buy NowMedium
AARD exhibits a medium-term uptrend characterized by higher highs and higher lows since mid-June, supported by rising EMAs. A recent Bearish Exhaustion pattern and oversold RSI suggest sellers are losing control, setting up a pullback into the 9/20/50 EMA zone. This pullback offers a favorable entry aligned with the bullish Stage 2 advance. We recommend buying now on the interaction with intermediate EMAs, with risk defined by a break below those levels.
- ↑Unique Prader-Willi niche; ARD-101 success could unlock unmet demand
- ↑$73.9M cash runway to late 2027; R&D spend cut to $10.5M
- ↓FDA’s full clinical hold halts ARD-101 HERO/OLE trials, delaying launch
Full analysis →